{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:04:39Z","timestamp":1759010679011},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2010,7,25]],"date-time":"2010-07-25T00:00:00Z","timestamp":1280016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s10096-010-1009-9","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T23:46:39Z","timestamp":1279928799000},"page":"1369-1375","source":"Crossref","is-referenced-by-count":13,"title":["In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998\u20132007"],"prefix":"10.1007","volume":"29","author":[{"given":"J.-C.","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.-I.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.-R.","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,25]]},"reference":[{"key":"1009_CR1","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1572-0241.2007.01393.x","volume":"102","author":"WD Chey","year":"2007","unstructured":"Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology (2007) American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102:1808\u20131825","journal-title":"Am J Gastroenterol"},{"key":"1009_CR2","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","volume":"56","author":"P Malfertheiner","year":"2007","unstructured":"Malfertheiner P, M\u00e9graud F, O\u2019Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ (2007) Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56:772\u2013781","journal-title":"Gut"},{"key":"1009_CR3","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1440-1746.2009.05982.x","volume":"24","author":"KM Fock","year":"2009","unstructured":"Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA; Second Asia-Pacific Conference (2009) Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 24:1587\u20131600","journal-title":"J Gastroenterol Hepatol"},{"key":"1009_CR4","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/gut.2003.022111","volume":"53","author":"F M\u00e9graud","year":"2004","unstructured":"M\u00e9graud F (2004) H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53:1374\u20131384","journal-title":"Gut"},{"key":"1009_CR5","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1053\/j.gastro.2007.07.008","volume":"133","author":"N Vakil","year":"2007","unstructured":"Vakil N, M\u00e9graud F (2007) Eradication therapy for Helicobacter pylori. Gastroenterology 133:985\u20131001","journal-title":"Gastroenterology"},{"key":"1009_CR6","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1572-0241.2006.00716.x","volume":"101","author":"EC Nista","year":"2006","unstructured":"Nista EC, Candelli M, Zocco MA, Cremonini F, Ojetti V, Finizio R, Spada C, Cammarota G, Gasbarrini G, Gasbarrini A (2006) Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol 101:1985\u20131990","journal-title":"Am J Gastroenterol"},{"key":"1009_CR7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1572-0241.2006.00637.x","volume":"101","author":"RJ Saad","year":"2006","unstructured":"Saad RJ, Schoenfeld P, Kim HM, Chey WD (2006) Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 101:488\u2013496","journal-title":"Am J Gastroenterol"},{"key":"1009_CR8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/dkp034","volume":"63","author":"CH Kuo","year":"2009","unstructured":"Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, Tsai PY, Wu IC, Wang SW, Li CJ, Weng BC, Chang LL, Jan CM, Wang WM, Wu DC (2009) Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 63:1017\u20131024","journal-title":"J Antimicrob Chemother"},{"key":"1009_CR9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2036.2006.02764.x","volume":"23","author":"WM Wong","year":"2006","unstructured":"Wong WM, Gu Q, Chu KM, Yee YK, Fung FM, Tong TS, Chan AO, Lai KC, Chan CK, Wong BC (2006) Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 23:421\u2013427","journal-title":"Aliment Pharmacol Ther"},{"key":"1009_CR10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1523-5378.2009.00709.x","volume":"14","author":"H Yoon","year":"2009","unstructured":"Yoon H, Kim N, Lee BH, Hwang TJ, Lee DH, Park YS, Nam RH, Jung HC, Song IS (2009) Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter 14:77\u201385","journal-title":"Helicobacter"},{"key":"1009_CR11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1523-5378.2006.00436.x","volume":"11","author":"P Bogaerts","year":"2006","unstructured":"Bogaerts P, Berhin C, Nizet H, Glupczynski Y (2006) Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 11:441\u2013445","journal-title":"Helicobacter"},{"key":"1009_CR12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijantimicag.2006.11.007","volume":"29","author":"V Cattoir","year":"2007","unstructured":"Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, M\u00e9graud F, Soussy CJ, Cambau E (2007) Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 29:389\u2013396","journal-title":"Int J Antimicrob Agents"},{"key":"1009_CR13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1128\/AAC.00614-06","volume":"51","author":"E Glocker","year":"2007","unstructured":"Glocker E, Stueger HP, Kist M (2007) Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 51:346\u2013349","journal-title":"Antimicrob Agents Chemother"},{"key":"1009_CR14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1523-5378.2009.00655.x","volume":"14","author":"KH Hung","year":"2009","unstructured":"Hung KH, Sheu BS, Chang WL, Wu HM, Liu CC, Wu JJ (2009) Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 14:61\u201365","journal-title":"Helicobacter"},{"key":"1009_CR15","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/jac\/dki334","volume":"56","author":"JM Kim","year":"2005","unstructured":"Kim JM, Kim JS, Kim N, Jung HC, Song IS (2005) Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 56:965\u2013967","journal-title":"J Antimicrob Chemother"},{"key":"1009_CR16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/jac\/47.3.360","volume":"47","author":"HW Minehart","year":"2001","unstructured":"Minehart HW, Chalker AF (2001) In vitro activity of gemifloxacin against Helicobacter pylori. J Antimicrob Chemother 47:360\u2013361","journal-title":"J Antimicrob Chemother"},{"key":"1009_CR17","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1128\/AAC.00078-09","volume":"53","author":"HJ Adam","year":"2009","unstructured":"Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG (2009) In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother 53:4915\u20134920","journal-title":"Antimicrob Agents Chemother"},{"key":"1009_CR18","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/jac\/dkp370","volume":"64","author":"YH Chen","year":"2009","unstructured":"Chen YH, Liu CY, Lu JJ, King CH, Hsueh PR (2009) In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J Antimicrob Chemother 64:1226\u20131229","journal-title":"J Antimicrob Chemother"},{"key":"1009_CR19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/dkp144","volume":"64","author":"CC Lai","year":"2009","unstructured":"Lai CC, Tan CK, Lin SH, Liao CH, Chou CH, Hsu HL, Huang YT, Hsueh PR (2009) Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J Antimicrob Chemother 64:73\u201378","journal-title":"J Antimicrob Chemother"},{"key":"1009_CR20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jac\/dkp174","volume":"64","author":"CK Tan","year":"2009","unstructured":"Tan CK, Lai CC, Liao CH, Chou CH, Hsu HL, Huang YT, Hsueh PR (2009) Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 64:428\u2013429","journal-title":"J Antimicrob Chemother"},{"key":"1009_CR21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1128\/AAC.00682-09","volume":"54","author":"L Lin","year":"2010","unstructured":"Lin L, Chang LW, Tsai CY, Hsu CH, Chung DT, Aronstein WS, Ajayi F, Kuzmak B, Lyon RA (2010) Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Antimicrob Agents Chemother 54:405\u2013410","journal-title":"Antimicrob Agents Chemother"},{"key":"1009_CR22","first-page":"1316","volume":"92","author":"JC Yang","year":"1997","unstructured":"Yang JC, Wang TH, Wang HJ, Kuo CH, Wang JT, Wang WC (1997) Genetic analysis of the cytotoxin-associated gene and the vacuolating toxin gene in Helicobacter pylori strains isolated from Taiwanese patients. Am J Gastroenterol 92:1316\u20131321","journal-title":"Am J Gastroenterol"},{"key":"1009_CR23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2125.2009.03393.x","volume":"67","author":"JC Yang","year":"2009","unstructured":"Yang JC, Yang YF, Uang YS, Lin CJ, Wang TH (2009) Pharmacokinetic\u2013pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. Br J Clin Pharmacol 67:503\u2013510","journal-title":"Br J Clin Pharmacol"},{"key":"1009_CR24","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2009) Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. M100-S19. CLSI, Wayne, PA"},{"key":"1009_CR25","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1099\/jmm.0.45642-0","volume":"53","author":"S Fujimura","year":"2004","unstructured":"Fujimura S, Kato S, Iinuma K, Watanabe A (2004) In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children. J Med Microbiol 53:1019\u20131022","journal-title":"J Med Microbiol"},{"key":"1009_CR26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1586\/eri.09.113","volume":"8","author":"L Boyanova","year":"2010","unstructured":"Boyanova L, Mitov I (2010) Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther 8:59\u201370","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1009_CR27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1523-5378.2009.00714.x","volume":"14","author":"N Horiki","year":"2009","unstructured":"Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Iizuka Y, Fukuda K, Fujita Y, Katsurahara M, Ito T, Cesar GE, Imoto I, Takei Y (2009) Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter 14:86\u201390","journal-title":"Helicobacter"},{"key":"1009_CR28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1523-5378.2006.00415.x","volume":"11","author":"H Miyachi","year":"2006","unstructured":"Miyachi H, Miki I, Aoyama N, Shirasaka D, Matsumoto Y, Toyoda M, Mitani T, Morita Y, Tamura T, Kinoshita S, Okano Y, Kumagai S, Kasuga M (2006) Primary levofloxacin resistance and gyrA\/B mutations among Helicobacter pylori in Japan. Helicobacter 11:243\u2013249","journal-title":"Helicobacter"},{"key":"1009_CR29","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1128\/AAC.48.12.4843-4847.2004","volume":"48","author":"JM Kim","year":"2004","unstructured":"Kim JM, Kim JS, Jung HC, Kim N, Kim YJ, Song IS (2004) Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother 48:4843\u20134847","journal-title":"Antimicrob Agents Chemother"},{"key":"1009_CR30","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1046\/j.1523-5378.2002.00096.x","volume":"7","author":"L Perez Aldana","year":"2002","unstructured":"Perez Aldana L, Kato M, Nakagawa S, Kawarasaki M, Nagasako T, Mizushima T, Oda H, Kodaira J, Shimizu Y, Komatsu Y, Zheng R, Takeda H, Sugiyama T, Asaka M (2002) The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 7:306\u2013309","journal-title":"Helicobacter"},{"key":"1009_CR31","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1440-1746.2009.05829.x","volume":"24","author":"WL Chang","year":"2009","unstructured":"Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ (2009) Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 24:1230\u20131235","journal-title":"J Gastroenterol Hepatol"},{"key":"1009_CR32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1128\/AAC.39.1.107","volume":"39","author":"RA Moore","year":"1995","unstructured":"Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE (1995) Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 39:107\u2013111","journal-title":"Antimicrob Agents Chemother"},{"key":"1009_CR33","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/AAC.47.12.3942-3944.2003","volume":"47","author":"J Tankovic","year":"2003","unstructured":"Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ (2003) Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 47:3942\u20133944","journal-title":"Antimicrob Agents Chemother"},{"key":"1009_CR34","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/jcp.2008.060392","volume":"61","author":"M Romano","year":"2008","unstructured":"Romano M, Iovene MR, Russo MI, Rocco A, Salerno R, Cozzolino D, Pilloni AP, Tufano MA, Vaira D, Nardone G (2008) Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol 61:1112\u20131115","journal-title":"J Clin Pathol"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-010-1009-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-010-1009-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-010-1009-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T09:34:19Z","timestamp":1559122459000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-010-1009-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,25]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["1009"],"URL":"https:\/\/doi.org\/10.1007\/s10096-010-1009-9","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2010,7,25]]}}}